Medication info

Empagliflozin/Metformin Extended-Release Tablet 12.5/750 mg (Empagliflozin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride with Colloidal Anhydrous Silica›757.5mg / 1 tabletEmpagliflozin›12.5mg / 1 tablet
Manufacturer / importer
Daewon Pharmaceutical Co., Ltd.
Appearance
Pink oval extended-release film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202501912 · Approved 2025.07.25

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and metformin hydrochloride extended-release 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily with the evening meal. Take one tablet of this medicine 10/1000 mg extended-release tablet or 25/1000 mg extended-release tablet once daily. Patients taking this medicine 5/1000 mg extended-release tablet, 12.5/1000 mg extended-release tablet, 5/750mg extended-release tablet, or 12.5/750mg extended-release tablet should take 2 tablets together once daily. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. ⦁ For patients who are unable to achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the recommended initial total daily dose when taking this medicine is empagliflozin 10 mg plus the patient's current metformin dose. If empagliflozin 10 mg is well tolerated but additional glycemic control is needed, the dose of empagliflozin may be increased to 25 mg. ⦁ Patients switching from concomitant empagliflozin and metformin therapy to this medicine should receive their previous doses of empagliflozin and metformin. When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and the dose appropriately adjusted. Because dosage adjustment is required according to renal function, assessment of renal function is recommended before starting this medicine and periodically during treatment. No dosage adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2] who tolerate treatment well and have no other condition that may increase the risk of lactic acidosis, this medicine may be used with adjustment of the metformin hydrochloride dose as follows. - The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to below 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to below 45 ml/min/1.73m2, discontinue this medicine immediately. In patients 75 years of age and older, consider renal function and the risk of volume depletion.

Ingredients

Manufacturer
Daewon Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

View approved original text

This medication is used to assist in blood sugar control for adult patients with type 2 diabetes when used in conjunction with Empagliflozin and Metformin as adjunct therapy to diet and exercise. It is particularly effective for patients who do not achieve sufficient blood sugar control, and should be used under the guidance of a specialist in cases of cardiovascular disease. This medication is effective in improving blood sugar levels and assisting in diabetes management.

How to take

Adult dose

For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and metformin hydrochloride extended-release 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily with the evening meal. Take one tablet of this medicine 10/1000 mg extended-release tablet or 25/1000 mg extended-release tablet once daily. Patients taking this medicine 5/1000 mg extended-release tablet, 12.5/1000 mg extended-release tablet, 5/750mg extended-release tablet, or 12.5/750mg extended-release tablet should take 2 tablets together once daily. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. ⦁ For patients who are unable to achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the recommended initial total daily dose when taking this medicine is empagliflozin 10 mg plus the patient's current metformin dose. If empagliflozin 10 mg is well tolerated but additional glycemic control is needed, the dose of empagliflozin may be increased to 25 mg. ⦁ Patients switching from concomitant empagliflozin and metformin therapy to this medicine should receive their previous doses of empagliflozin and metformin. When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and the dose appropriately adjusted. Because dosage adjustment is required according to renal function, assessment of renal function is recommended before starting this medicine and periodically during treatment. No dosage adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2] who tolerate treatment well and have no other condition that may increase the risk of lactic acidosis, this medicine may be used with adjustment of the metformin hydrochloride dose as follows. - The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to below 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to below 45 ml/min/1.73m2, discontinue this medicine immediately. In patients 75 years of age and older, consider renal function and the risk of volume depletion.

Precautions

This medication consists of two components, Metformin and Empagliflozin, and is primarily used in the treatment of type 2 diabetes. While taking this medication, there is a rare possibility of serious lactic acidosis occurring, so caution is particularly necessary for patients with impaired kidney function or those with heart or liver disease. When used with other diabetes medications, hypoglycemic symptoms may occur, so blood sugar levels should be closely monitored. This medication should not be used in patients with moderate to severe impairment of kidney function, acute kidney injury, dehydration, severe infection, or heart failure. It should be temporarily discontinued before any examination involving iodine contrast agents, and administration should be resumed only after confirming that kidney function has returned to normal post-examination. Pregnant women or women who may become pregnant, as well as nursing mothers, should avoid using this medication. This medication may increase the risk of genital and urinary tract infections, so immediate consultation with healthcare professionals is required if any signs of infection appear. From the time of use, if symptoms such as hypoglycemia, abdominal pain, muscle pain, difficulty breathing, weakness, or other adverse effects occur, the patient should inform a physician immediately. Elderly patients or those with compromised kidney function should regularly have their kidney function evaluated, and dose adjustments should be made if necessary. It is advisable to avoid alcohol consumption while using this medication, and this medication may be temporarily paused in case of dehydration, diarrhea, or vomiting. This medication should be swallowed whole and should not be chewed or broken, although the tablet shell may be excreted in the stool, which is normal. If there are other medications being used concurrently, there may be potential for drug interactions, so all medications being taken should be disclosed to healthcare personnel. In the case of overdose, serious side effects such as lactic acidosis may occur, necessitating immediate treatment at a hospital.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • hypoglycemia
  • urinary tract infection
  • genital infection
  • increased urination
  • decreased vitamin B12 and deficiency
  • ketoacidosis
  • lactic acidosis
  • decreased fluid volume
Show 152 more
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
  • constipation
  • abnormal liver function tests
  • hepatitis
  • taste disturbance
  • itching
  • rash
  • hives
  • erythema
  • angioedema
  • dysuria
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • nausea
  • malaise
  • gastric ulcer
  • colitis
  • ischemic colitis
  • bowel bleeding
  • chronic gastritis
  • constipation
  • gastritis
  • abdominal discomfort
  • anal incontinence
  • dry mouth
  • gastrointestinal disorders
  • gastroesophageal reflux disease
  • oral discomfort
  • salivary gland pain
  • headache
  • dizziness
  • orthostatic dizziness
  • drowsiness
  • facial paralysis
  • memory disturbances
  • neuralgia
  • Parkinsonism
  • polyneuropathy
  • sensory disturbances
  • CNS-origin dizziness
  • fatigue
  • peripheral edema
  • facial edema
  • peripheral swelling
  • fever
  • facial swelling
  • chills
  • strange sensations
  • swelling
  • pain
  • pain at the puncture site
  • vascular stent stenosis
  • vascular stent thrombosis
  • chest pain
  • weight loss
  • urinary stones
  • hematuria
  • overactive bladder
  • renal mass
  • urinary retention
  • abnormal urination
  • vulvar pruritus
  • benign prostatic hyperplasia
  • erectile dysfunction
  • atrophic vaginitis
  • cervical dysplasia
  • cervical inflammation
  • scrotal pain
  • sexual dysfunction
  • vaginal discharge
  • dyslipidemia
  • hyperglycemia
  • hyponatremia
  • dermal cysts
  • seborrheic dermatitis
  • atopic dermatitis
  • diabetic foot
  • nummular eczema
  • sweat rash
  • sebaceous gland hyperplasia
  • lumbar spinal canal stenosis
  • myalgia
  • limb pain
  • musculoskeletal chest pain
  • arthralgia
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscle weakness
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataracts
  • allergic conjunctivitis
  • blurred vision
  • corneal erosion
  • glaucoma
  • macular fibrosis
  • eye discomfort
  • eye congestion
  • pathological myopia
  • retinal detachment
  • retinal crystals
  • retinal vein occlusion
  • macular retinal detachment
  • eyelid swelling
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • nasal bleeding
  • asthma
  • exertional dyspnea
  • productive cough
  • allergic rhinitis
  • residual sputum
  • cough
  • skin lacerations
  • rib fractures
  • ligament strain syndrome
  • angina
  • palpitations
  • Prinzmetal angina
  • coronary artery disease
  • tachycardia
  • atherosclerosis
  • deep vein thrombosis
  • diabetic vascular diseases
  • peripheral artery occlusive disease
  • anxiety
  • depression
  • sleep disorders
  • acute cholecystitis
  • autoimmune hepatitis
  • cholelithiasis
  • hepatitis
  • otalgia
  • orthostatic dizziness
  • dizziness
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid nodules
  • unstable angina

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect from air and moisture, at a cool room temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Pink oval extended-release film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.